These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 26787689

  • 1. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.
    VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
    Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
    VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2809-14. PubMed ID: 23629705
    [Abstract] [Full Text] [Related]

  • 5. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 7. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O.
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [Abstract] [Full Text] [Related]

  • 8. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [Abstract] [Full Text] [Related]

  • 9. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J, Malbrain ML, Havel E, Šafránek P, Bezouška J, Kaška M.
    Anaesthesiol Intensive Ther; 2016 Jan; 48(1):23-8. PubMed ID: 26588478
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T, Kanazawa S, Hara T, Izawa M, Sato T, Yamaguchi T, Tsuji M, Maki H.
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
    Tamme K, Oselin K, Kipper K, Tasa T, Metsvaht T, Karjagin J, Herodes K, Kern H, Starkopf J.
    Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
    [Abstract] [Full Text] [Related]

  • 12. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
    Abodakpi H, Chang KT, Gao S, Sánchez-Díaz AM, Cantón R, Tam VH.
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [Abstract] [Full Text] [Related]

  • 13. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q, Rand K, Derendorf H.
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [Abstract] [Full Text] [Related]

  • 14. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
    Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4134-8. PubMed ID: 23774429
    [Abstract] [Full Text] [Related]

  • 15. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [Abstract] [Full Text] [Related]

  • 16. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
    Lister PD, Prevan AM, Sanders CC.
    Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
    Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN.
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
    [Abstract] [Full Text] [Related]

  • 18. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
    Ambrose PG, Bhavnani SM, Jones RN.
    Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD, Le P, Church DL, Gregson DB, Laupland KB.
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.